Top Markets
Coin of the day
Hansa Biopharma AB Hansa Biopharma AB

Hansa Biopharma AB

HNSBF
Rang in aandelen #15162
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development... Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Aandeelprijs
$3.70
Laatst gesynchroniseerd: 2026-08-28
Marktkapitalisatie
$369.01M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
35.04%
Land
SE
Handel Hansa Biopharma AB (HNSBF)

Categorie

Aandelsplitsingen voor Hansa Biopharma AB (HNSBF)
Het aandeel Hansa Biopharma AB (symbool: HNSBF) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Sep 01, 2026.
Eén aandeel HNSBF dat vóór Sep 01, 2026 werd gekocht, staat nu gelijk aan 0 aandelen HNSBF.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten